Oppenheimer analyst Jay Olson downgraded Exelixis (EXEL) to Perform from Outperform.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Jefferies has two ‘contradictory’ conclusions after Exelixis abstract release
- Exelixis falls after ASCO releases colorectal cancer data
- Exelixis price target raised to $41 from $38 at Oppenheimer
- Exelixis price target raised to $42 from $38 at Truist
- Exelixis price target raised to $41 from $34 at JMP Securities